M&A News

$Biogen (BIIB.US)$ 📣 Acquires Human Immunology Biosciences (HI-Bio)

⇨ Expands immunology portfolio 🧬

⇨ $1.15B upfront and up to $650M potential milestone payments 💰

⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial